Zai Lab Ltd- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Zai Lab Ltd 公司

Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.

Zai Lab Ltd簡介



公司代碼ZLAB

公司名稱Zai Lab Ltd

上市日期Sep 28, 2020

CEODu (Ying)

員工數量1869

證券類型Depository Receipt

年結日Sep 28

公司地址Building B, 899 Halei Road, Pudong

城市SHANGHAI

上市交易所NASDAQ OMX - NASDAQ BASIC

國家China

郵編201203

電話862161632588

網址https://www.zailaboratory.com/

公司代碼ZLAB

上市日期Sep 28, 2020

CEODu (Ying)

Zai Lab Ltd公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. John David Diekman, Ph.D.

Lead Independent Director

99.77K

+10831.00%

Mr. Joshua L. Smiley

President, Chief Operating Officer

86.60K

+10000.00%

Mr. William David (Bill) Lis

Independent Director

35.11K

-2983.00%

Dr. Yajing Chen, Ph.D.

Chief Financial Officer

17.44K

-240.00%

Dr. Ying (Samantha) Du, Ph.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

--

Ms. Leung (Nisa Bernice) Wing-Yu

Independent Director

--

Mr. Peter Karl Wirth, J.D.

Independent Director

--

Mr. Leon Oliver (Lonnie) Moulder, Jr.

Independent Director

--

Mr. Frazor Titus Edmondson, J.D.

Company Secretary, Chief Legal Officer

--

Mr. Scott W. Morrison, CPA

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Dr. John David Diekman, Ph.D.

Lead Independent Director

99.77K

+10831.00%

Mr. Joshua L. Smiley

President, Chief Operating Officer

86.60K

+10000.00%

Mr. William David (Bill) Lis

Independent Director

35.11K

-2983.00%

Dr. Yajing Chen, Ph.D.

Chief Financial Officer

17.44K

-240.00%

Dr. Ying (Samantha) Du, Ph.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

--

Ms. Leung (Nisa Bernice) Wing-Yu

Independent Director

--

收入明細

單位: USD更新時間: 1月6日週二

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

業務USD

名稱

營收

佔比

ZEJULA

42.43M

36.78%

VYVGART

27.73M

24.03%

NUZYRA

15.43M

13.38%

Optune

12.66M

10.97%

QINLOCK

8.90M

7.72%

其他

8.21M

7.12%

地區USD

名稱

營收

佔比

China (Mainland)

116.09M

0.00%

業務

地區

業務USD

名稱

營收

佔比

ZEJULA

42.43M

36.78%

VYVGART

27.73M

24.03%

NUZYRA

15.43M

13.38%

Optune

12.66M

10.97%

QINLOCK

8.90M

7.72%

其他

8.21M

7.12%

股東統計

更新時間: 2月7日週六

持股股東

股東類型

持股股東

佔比

Capital World Investors

5.39%

Fidelity Management & Research Company LLC

3.79%

Norges Bank Investment Management (NBIM)

3.41%

ClearBridge Investments, LLC

3.12%

RTW Investments L.P.

2.03%

其他

82.26%

持股股東

佔比

Capital World Investors

5.39%

Fidelity Management & Research Company LLC

3.79%

Norges Bank Investment Management (NBIM)

3.41%

ClearBridge Investments, LLC

3.12%

RTW Investments L.P.

2.03%

其他

82.26%

股東類型

持股股東

佔比

Investment Advisor

15.68%

Investment Advisor/Hedge Fund

12.47%

Sovereign Wealth Fund

3.58%

Hedge Fund

2.94%

Individual Investor

1.78%

Private Equity

1.44%

Venture Capital

1.12%

Research Firm

0.61%

Pension Fund

0.02%

其他

60.34%

機構持股



更新時間: 1月21日週三

報告期間

機構數

持股數

持股佔比

持股變動

2026Q4

280

37.42M

42.38%

--

2025Q4

370

44.73M

39.84%

-12.84M

2025Q3

372

46.61M

41.70%

-15.37M

2025Q2

394

60.58M

54.15%

-11.96M

2025Q1

453

59.51M

53.68%

-14.18M

2024Q4

446

60.80M

55.47%

-4.29M

2024Q3

439

51.45M

51.99%

-10.14M

2024Q2

454

47.04M

47.66%

-14.67M

2024Q1

465

46.22M

46.47%

-13.77M

2023Q4

497

46.31M

46.92%

-16.57M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Capital World Investors

6.08M

5.43%

+41.48K

+0.69%

Sep 30, 2025

Fidelity Management & Research Company LLC

4.28M

3.82%

-610.67K

-12.50%

Sep 30, 2025

ClearBridge Investments, LLC

3.52M

3.14%

-492.62K

-12.28%

Sep 30, 2025

RTW Investments L.P.

2.29M

2.05%

-3.25M

-58.62%

Sep 30, 2025

Janus Henderson Investors

2.05M

1.83%

-148.32K

-6.75%

Sep 30, 2025

Wellington Management Company, LLP

1.72M

1.53%

+341.49K

+24.80%

Sep 30, 2025

Frazier Life Sciences Management, L.P.

1.63M

1.45%

+319.18K

+24.40%

Sep 30, 2025

Baron Capital Management, Inc.

1.37M

1.22%

-216.57K

-13.64%

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Tema Oncology ETF

1.67%

ALPS Medical Breakthroughs ETF

1.19%

Virtus LifeSci Biotech Products ETF

0.97%

Invesco Golden Dragon China ETF

0.58%

National Security Emerging Markets Index ETF

0.39%

iShares Biotechnology ETF

0.18%

Capital Group New Geography Equity ETF

0.15%

ProShares Ultra Nasdaq Biotechnology

0.12%

Invesco Nasdaq Biotechnology ETF

0.12%

ActivePassive International Equity ETF

0.03%

Tema Oncology ETF

佔比1.67%

ALPS Medical Breakthroughs ETF

佔比1.19%

Virtus LifeSci Biotech Products ETF

佔比0.97%

Invesco Golden Dragon China ETF

佔比0.58%

National Security Emerging Markets Index ETF

佔比0.39%

iShares Biotechnology ETF

佔比0.18%

Capital Group New Geography Equity ETF

佔比0.15%

ProShares Ultra Nasdaq Biotechnology

佔比0.12%

Invesco Nasdaq Biotechnology ETF

佔比0.12%

ActivePassive International Equity ETF

佔比0.03%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據